Sign up to our technology alerts and be the first to hear about any new technology opportunities from Scotland's universities
Please select the market sector you are interested in.
Please select the university you are interested in.
Show only Easy Access opportunities.
Narrow your search with a few keywords.
University: University of St Andrews
Sector(s): Life Sciences
In vitro tests show that using an echinocandin drug with an antimicrobial peptide provides a synergistic combination for treating a fungal infection.
Combination therapy potentially offers a new route to targeting fungal infections, including those caused by highly resistant fungi (e.g. Candida glabrata)Combination therapy leads to less drug resistance compared to single use drugs.Synergistic activity in combination therapy allows lower concentrations of expensive echinocandin drugs to be used, reducing potential toxicity and side effects and the cost of treatment
Echinocandin drugs (caspofungin, micafungin & anidulafungin) are first-line antifungal treatments for Candida and Aspergillus infections, but have limited effect on a broader range of fungal infections. Combination therapy could widen the applications for echinocandin drugs and lead to better, lower cost therapies for patients.
A UK patent application was filed on 18 September 2008, application number 0817121.7. This has been followed by PCT application PCT/GB2009/002226 in 2009.
Easy Access Documents:
Please enter your name.
Please enter the name of the company you work for.
Is your company an SME?
Please select the country you are in.
Please enter your email address.
Please enter your telephone number.
To help us process your enquiry faster please enter some details about the information you are interested in.
Please prove you are a human by completing this simple image recognition task.
The University of Glasgow has developed Soluble Polymer Catalysts, using organocatalysts for chiral chemical production...
University of Glasgow scientists have borrowed techniques employed in the semi-conductor industry to pattern the surfaces of either hard or soft materials and render these surfaces less adhesive to cells.
Scientists at the University of Glasgow have pioneered a new sensor technology, Lab-in-a-Pill, that could have major impact on the cost and effectiveness of bowel cancer treatment.
The Thermoelectric Sensor technology is a Nano-Calorimetric Sensor which measures very small changes in temperature. The IP provides a route to making the most sensitive calorimetric measurements (with a resolution of 0.1 mK).
The University of Glasgow is offering an exciting new model for the evaluation of new treatments for Parkinsons disease